Answers are grounded in this paper and cite their sources.
Observational analysis identifies gaps in evidence for endometrial protection using an intrauterine system with estrogen therapy, indicating potential benefits and limitations.
The levonorgestrel intrauterine system (IUS) is frequently used in perimenopause for contraception and bleeding control and in both perimenopause and menopause for endometrial protection while using estrogen therapy to control bothersome menopause symptoms. The use of an IUS for endometrial protection as part of hormone therapy is off label in the United States but is approved for use in more than 100 countries for up to 5 years. Some IUSs have been approved for contraceptive use for 8 years, and questions remain whether they provide adequate endometrial protection when combined with estrogen therapy beyond 5 years of use.
No takes yet. Share an insight, caveat, or question.
Amy J. Voedisch (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: